Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Omega-3 fatty acids not effective for depression in CHD patients (POEM)

POEM (Patient Oriented Evidence that Matters)

Clinical question

Does supplementation with omega-3 fatty acids improve the response to sertraline in patients with major depression and coronary heart disease?

Bottom line

In this study, the addition of omega-3 fatty acids to sertraline in patients with major depression and coronary heart disease did not result in more effective treatment of the depression at 10 weeks compared with sertraline alone.

Synopsis

Investigators identified 122 adults with a mean age of 58 years who had a history of coronary heart disease and a current major depressive episode. Eligible patients randomly received (allocation concealed) sertraline 50mg daily plus either 2g omega-3 fatty acid daily or corn oil placebo for 10 weeks.

Individuals, who were masked to treatment group assignment, evaluated study participants at baseline, at four weeks and 10 weeks using standard validated scoring tools for depression and anxiety. Complete follow-up occurred for 94 per cent of participants at 10 weeks.

Using intention-to-treat analysis, no significant differences in improvement rates occurred between the two intervention groups. Adverse event rates were also similar in both groups. The study was 90 per cent powered to detect a predetermined clinically significant treatment difference (difference of 4 points or more on the scoring tools).

Level of evidence

1b (randomised controlled trial with narrow confidence interval)

Reference

Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease. A randomized controlled trial.

JAMA 2009;302(15):1651–7.

Funding

Industry and government

 

POEM (Patient Oriented Evidence that Matters) © 1995-2009 John Wiley & Sons, Inc. or related companies. All Rights reserved.

www.essentialevidenceplus.com

Citation: The Pharmaceutical Journal URI: 10989700

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.